A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
A S PallerE C SiegfriedE L SimpsonM J CorkB LockshinM P KosloskiM A KamalJ D DavisX SunG PirozziN M H GrahamA GadkariLaurent EckertM RuddyAshish BansalPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Single-dose dupilumab was generally well tolerated and substantially reduced clinical signs/symptoms of AD. Slightly better responses were seen in older than younger children. The pharmacokinetics of dupilumab were non-linear, consistent with previous studies in adults and adolescents.